Clovis Oncology

FDA rejects Clovis' long-shot bid for approval of Rubraca
FDA rejects Clovis' long-shot bid for approval of Rubraca
Fierce Pharma
Clovis Oncology
Rubraca
FDA
bankruptcy
Flag link:
Clovis sells off remaining assets—including cancer drug Rubraca—for $70M-plus
Clovis sells off remaining assets—including cancer drug Rubraca—for $70M-plus
Fierce Pharma
Clovis Oncology
Rubraca
bankruptcy
Pharma & Schweiz
Flag link:
Amid bankruptcy, Clovis reveals more regulatory troubles for Rubraca
Amid bankruptcy, Clovis reveals more regulatory troubles for Rubraca
Fierce Pharma
Clovis Oncology
Rubraca
ovarian cancer
bankruptcy
Flag link:
Clovis files for bankruptcy, will keep operating and plans to sell pipeline asset to Novartis
Clovis files for bankruptcy, will keep operating and plans to sell pipeline asset to Novartis
Endpoints
Clovis Oncology
bankruptcy
Novartis
Flag link:
In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use
In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use
Fierce Pharma
Clovis Oncology
Rubraca
FDA
ovarian cancer
Flag link:
With the walls closing in for Clovis, FDA demands ovarian cancer restriction for Rubraca
With the walls closing in for Clovis, FDA demands ovarian cancer restriction for Rubraca
Fierce Biotech
Clovis Oncology
Rubraca
ovarian cancer
FDA
Flag link:
Clovis Oncology flags possible bankruptcy in 'very near term'
Clovis Oncology flags possible bankruptcy in 'very near term'
NASDAQ
Clovis Oncology
bankruptcy
Rubraca
Flag link:
As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win
As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win
Fierce Pharma
Clovis Oncology
Rubraca
ovarian cancer
prostate cancer
Flag link:
ESMO 2022 movers – KRAS backfires
ESMO 2022 movers – KRAS backfires
EP Vantage
ESMO
KRAS inhibitors
Relay Therapeutics
Regeneron
Amgen
Deciphera
Clovis Oncology
Ayala Pharmaceuticals
Springworks
Mirati Therapeutics
Flag link:
Undeterred by FDA warning, desperate Clovis seeks Rubraca nod in front-line ovarian cancer
Undeterred by FDA warning, desperate Clovis seeks Rubraca nod in front-line ovarian cancer
Fierce Pharma
Clovis Oncology
Rubraca
FDA
ovarian cancer
Flag link:
Clovis, in need of cash or deals now to stem looming financial challenges, looks to pipeline for ideas
Clovis, in need of cash or deals now to stem looming financial challenges, looks to pipeline for ideas
Fierce Biotech
Clovis Oncology
Rubraca
ovarian cancer
funding
Flag link:
Why Clovis Oncology Stock Went Into Retreat Mode This Week
Why Clovis Oncology Stock Went Into Retreat Mode This Week
Motley Fool
Clovis Oncology
Rubraca
Flag link:
Why Clovis Oncology Stock Was Blasting Off Tuesday
Why Clovis Oncology Stock Was Blasting Off Tuesday
Motley Fool
Clovis Oncology
clinical trials
FAP-2286
solid tumors
Flag link:
Clovis quietly unveils crippling FDA delay as its troubles deepen
Clovis quietly unveils crippling FDA delay as its troubles deepen
Fierce Pharma
Clovis Oncology
FDA
Rubraca
ovarian cancer
Flag link:
Clovis equity investors overlook two elephants
Clovis equity investors overlook two elephants
EP Vantage
Clovis Oncology
Rubraca
ovarian cancer
Flag link:
Corcept, Clovis Score Wins in Advanced Ovarian Cancer
Corcept, Clovis Score Wins in Advanced Ovarian Cancer
BioSpace
Clovis Oncology
Corcept Therapeutics
ovarian cancer
clinical trials
Flag link:
Clovis Oncology, Evergreen partner for actinium-225-labeled FAP-2286
Clovis Oncology, Evergreen partner for actinium-225-labeled FAP-2286
Pharmaceutical Business Review
Clovis Oncology
Evergreen Theragnostics
radiolabeling
Flag link:
ASCO-GU – prostate cancer PARPS move to the front line
ASCO-GU – prostate cancer PARPS move to the front line
EP Vantage
prostate cancer
ASCO-GU
PARP inhibitors
Lynparza
Zejula
Rubraca
Talzenna
biomarkers
AstraZeneca
Merck
GSK
JNJ
Clovis Oncology
Flag link:
Why Clovis Oncology Shares Got a Bump This Week
Why Clovis Oncology Shares Got a Bump This Week
Motley Fool
Clovis Oncology
earnings
Rubraca
Flag link:
Clovis spikes ovarian cancer combo after 'underwhelming' efficacy; Servier wins priority review for Tibsovo expansion
Clovis spikes ovarian cancer combo after 'underwhelming' efficacy; Servier wins priority review for Tibsovo expansion
Endpoints
Clovis Oncology
earnings
Lucitanib
Opdivo
Bristol Myers Squibb
ovarian cancer
Flag link:

Pages